Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{210700,
        author = {Vithal R. Bhandare and Mythili K. Jeedigunta and Shailaja Mallya and Ashutosh P. Kamble and Sakshi B. Parsutkar and Aarti V. Shingan.},
        title = {APPLICATION OF NETWORK PHARMACOLOGY IN THE PALLIATIVE MANAGEMENT OF NEURODEGENERATIVE DISORDERS},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {6},
        pages = {2028-2039},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=210700},
        abstract = {Neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis, are progressive conditions driven by interacting molecular processes such as abnormal protein handling, neuroinflammation, oxidative stress, mitochondrial dysfunction, synaptic failure and altered neurotransmission. Their burden extends beyond neurological impairment and frequently includes pain, sleep disruption, anxiety, depression, fatigue, dysphagia, spasticity, autonomic symptoms, cognitive decline and caregiver distress. Palliative care addresses these multidimensional needs through early, continuous and person-centred symptom relief and is not restricted to end-of-life care. Network pharmacology provides a systems-level framework for examining relationships among compounds, molecular targets, signalling pathways, disease phenotypes and drug combinations. By integrating curated databases, transcriptomic and proteomic evidence, protein–protein interaction networks, pathway enrichment, molecular docking and experimental validation, it may help prioritize multi-target candidates relevant to disease mechanisms and symptom burden. This review discusses the principles and workflow of network pharmacology in neurodegeneration, disease-specific and cross-disease networks, and opportunities for drug repurposing and natural-product research in support of palliative objectives. It emphasizes the distinction between computational prediction and demonstrated clinical benefit. Network pharmacology is not itself a palliative intervention and cannot replace multidisciplinary care. Its potential contribution is to prioritize testable candidates, identify interaction risks and support symptom-oriented therapeutic hypotheses. Limitations include database bias, target-prediction uncertainty, blood–brain barrier constraints, disease-stage effects, polypharmacology-related toxicity and limited clinical validation. A translational framework linking patient-defined needs to reproducible computational analysis, experimental confirmation and patient-centred clinical evaluation is proposed.},
        keywords = {Network pharmacology; neurodegenerative disorders; palliative care; Alzheimer’s disease; Parkinson’s disease; amyotrophic lateral sclerosis; Huntington’s disease; systems biology; polypharmacology; quality of life.},
        month = {November},
        }